Status:
TERMINATED
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments
Lead Sponsor:
Centre Hospitalier Régional d'Orléans
Collaborating Sponsors:
CNRS - Pr Chantal PICHON
Conditions:
HPV Infection
Vaginal Cancer
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx. The International ...
Detailed Description
In this project, the investigators want to develop organotypic culture of primary-derived biopsies, and combine them with organ-on-a-chip technology, to better characterize the HPV infection and cance...
Eligibility Criteria
Inclusion
- Patients between 18 and 75 years old.
- Patients presented with cervical or vaginal dysplasia or cancer induced by oncogenic HPV demonstrated by a PAP test and or HPV testing requiring a biopsy and histology in current care.
- Patients with previous history of conisation or hysterectomy for lesions of the cervix or the vagina caused by oncogenic HPV.
- To participate in the study, patients must sign an informed consent.
Exclusion
- \- Pregnant women
- Patients with coagulation disorders
- Refusal of patients to participate in the trial Patients not affiliated to medical insurance
- Person deprived of their liberty by judicial or administrative decision
- Adults over 18 who are under legal protection measures or cannot give their consent
Key Trial Info
Start Date :
December 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 21 2021
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04278326
Start Date
December 21 2021
End Date
December 21 2021
Last Update
April 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHR Orléans
Orléans, France, 45000